Marksans Pharma’s wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.  These are prescription medications primarily used to treat high blood pressure.

Relonchem holds more than 160 product licences and supplies a wide range of own-label pharmaceutical products across multiple therapeutic areas, including anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, allergy relief, anti-viral, and pain relief medicines for the UK market.

Headquartered in Mumbai, Marksans Pharma has established a strong global presence, operating in over 50 countries. The company is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across key therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterology, and anti-allergy. Its manufacturing facilities in India, the USA, and the UK are approved by major regulatory agencies, including the USFDA, UKMHRA, and the Australian TGA.